Advertisement

Clinical Pharmacokinetics

, Volume 4, Issue 3, pp 170–199 | Cite as

Clinical Pharmacokinetics of Aminoglycoside Antibiotics

  • Jean-Claude Pechere
  • Robert Dugal
Article

Summary

The pharmacokinetics of widely used and of investigated aminoglycosides, namely kanamycin, gentamicin, tobramycin, amikacin, sisomicin and netilmicin, in normal volunteers and in patients with physiological states and disturbances known to alter their disposition are critically examined in view of recent developments. Analytical methods for the assay of aminoglycosides in biological fluids are briefly but critically described. Emphasis is placed on multicompartmental characterisation of aminoglycoside kinetics, especially as it relates to certain heretofore unexplained observations such as tissue accumulation and delayed elimination. Other components of the kinetic profile of aminoglycosides are reviewed. For practical purposes, aminoglycosides are neither protein bound nor biotransformed. The major route of elimination is glomerular filtration, and aminoglycosides undergo some tubular reabsorption. Relevant pharmacokinetic parameters from significant studies have been tabulated. Some practical aspects of distribution kinetics are then presented. All aspects considered, and even though therapeutic concentrations can be obtained in some patients, the penetration of aminoglycoside into the cerebrospinal fluid, bronchial secretions and biliary tract remains somewhat unpredictable, depending in particular on the underlying diseases. When feasible, local treatment such as aerosols, intrathecal or intraventricular supplementation of parenteral administration are to be recommended.

Due to the almost exclusive excretion from the body by glomerular filtration, the elimination rate of aminoglycoside antibiotics is greatly affected by impairment of renal function. The mathematical relationships between pharmacokinetic parameters and renal function indicators are tabulated and discussed. The predictive potential of nomograms can be greatly improved by taking into consideration some physiological parameters such as sex, age, lean body mass, haematocrit and characterisation of disposition kinetics by multicompartmental models. However, actual serial monitoring of aminoglycoside concentrations in serum appears to be the most reliable method for therapeutic monitoring. Half-lives in patients with minimal renal function during haemodialysis, during peritoneal dialysis and during interdlalysis periods are tabulated and the practical implications of these data discussed.

In the neonatal period, the absorption rate after intramuscular injection appears to be faster than reported in adults and the volume of distribution is significantly larger. The major pharmacokinetic difference between neonates, infants and adults is the slower elimination: for instance, half-lives which average around 2 hours in adults with normal renal function can reach and sometimes exceed 5 to 6 hours during the very first days of life.

The volume of distribution per kilogram of body weight is relatively smaller in obese subjects and in dehydrated patients than in normal subjects and can lead to overdosing when dosages are calculated on a body weight basis. Anaemia, fever, hypoxaemia and major burns are other pathological states which significantly influence pharmacokinetics of aminoglycosides. Inactivation by heparin, carbenicillin and ticarcillin is reviewed.

The methods of administration currently favoured are briefly examined and a procedure which may be more applicable to the kinetics of aminoglycosides is suggested so that further comparative clinical trials may be undertaken of the assessment of the relative merits of different modes of administration.

Keywords

Gentamicin Clinical Pharmacology Peritoneal Dialysis Aminoglycoside Amikacin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Anhalt, J.P. and Brown, S.D.: High-performance liquid-chromatographic assay of aminoglycoside antibiotics in serum. Clinical Chemistry 24: 1940–1947 (1978).PubMedGoogle Scholar
  2. Atkins, R.C.; Mion, C. and Despaux, E.: Peritoneal transfer of kanamycin and its use in peritoneal dialysis. Kidney International 3: 391–396 (1973).PubMedCrossRefGoogle Scholar
  3. Barza, M.; Brown, R.B.; Shen, D.; Gibaldi, M. and Weinstein, L.: Predictability of blood levels of gentamicin in man. Journal of Infectious Diseases 132: 165–174 (1975).PubMedCrossRefGoogle Scholar
  4. Barza, M. and Lauermann, M.: Why monitor serum levels of gentamicin?. Clinical Pharmacokinetics 3: 202–215 (1978).PubMedCrossRefGoogle Scholar
  5. Barza, M. and Scheife, R.T.: Drug therapy reviews: antimicrobial spectrum, pharmacology and therapeutic use of antibiotics: part IV: aminoglycosides. American Journal of Hospital Pharmacy 34: 723–737 (1977).PubMedGoogle Scholar
  6. Beam, T.R. and Allen, J.C.: Blood brain and cerebrospinal fluid concentrations of several antibiotics in rabbits with intact and inflamed meninges. Antimicrobial Agents and Chemotherapy 12: 710–716 (1977).PubMedCrossRefGoogle Scholar
  7. Bechtol, L.D. and Black, H.R.: Tobramycin in renal impairment. American Journal of The Medical Sciences 269: 317–321 (1975).PubMedCrossRefGoogle Scholar
  8. Bergogne-Berezin, E.; Morel, C.; Even, P.; Benard, Y.; Kaffe, H.; Berthelot, G.; Pierre, J. and Lambert-Zechovsky, N.: Pharmacocinetique des antibiotiques dans les voies respiratoires. Nouvelle Presse Medicale 7: 2831–2836 (1978).PubMedGoogle Scholar
  9. Bjornsson, T.D.: The use of creatinine concentrations to determine renal function. Clinical Pharmacokinetics 4: 200–222 (1979).PubMedCrossRefGoogle Scholar
  10. Black, R.E.; Law, W.K.; Weinstein, R.J.; Young, L.S. and Hewitt, W.L.: Ototoxicity of amikacin. Antimicrobial Agents and Chemotherapy 9: 956–961 (1976).PubMedCrossRefGoogle Scholar
  11. Bodey, G.P.; Chang, H.-Y.; Rodriguez, V. and Stewart, D.: Feasibility of administering aminoglycoside antibiotics by continuous intravenous infusion. Antimicrobial Agents and Chemotherapy 8: 328–333 (1975).PubMedCrossRefGoogle Scholar
  12. Boger, W.P. and Gavin, J.J.: Kanamycin: its cerebrospinal fluid diffusion, renal clearance, and comparison with streptomycin; in Welch and Marti-Ibanez (Eds) Antibiotics Annual 1958–59, p. 677 (Medical Encyclopedia, New York 1959).Google Scholar
  13. Briedis, D.J. and Robson, H.G.: Cerebrospinal fluid penetration of amikacin. Antimicrobial Agents and Chemotherapy 13: 1042–1043 (1978).PubMedCrossRefGoogle Scholar
  14. Brogard, J.M.; Harf, C.; Pinguet, M. and Lavillaureix, J.: Tobramycine: donnees pharmacologiques chez l’homme. Nouvelle Presse Medicale 3 (Suppl): S59–S64 (1974).Google Scholar
  15. Brogden, R.N.; Pinder, R.M.; Sawyer, P.R.; Speight, T.M. and Avery, G.S.: Tobramycin: a review of its antibacterial and pharmacokinetic properties and therapeutic use. Drugs 12: 166–200 (1976).PubMedCrossRefGoogle Scholar
  16. Cabana, B.E. and Taggart, J.G.: Comparative pharmacokinetics of BB-K8 and kanamycin in dogs and humans. Antimicrobial Agents and Chemotherapy 3: 478–483 (1973).PubMedCrossRefGoogle Scholar
  17. Chiou, W.L. and Hsu, F.H.: Pharmacokinetics of creatinine in man and its implications in the monitoring of renal function and in dosage regimen modifications in patients with renal insufficiency. Journal of Clinical Pharmacology 15: 427–434 (1975).PubMedGoogle Scholar
  18. Chiu, P.J.S. and Long, J.F.: Effects of hydration on gentamicin excretion and renal accumulation in furosemide-treated rats. Antimicrobial Agents and Chemotherapy 14: 214–217 (1978).PubMedCrossRefGoogle Scholar
  19. Christopher, T.G.; Blair, A.D.; Forrey, A.W. and Cutler, R.E.: Hemodialyzer clearances of gentamicin, kanamycin, tobramycin, amikacin, ethambutol, procainamide and flucytosine with a technique for planning therapy. Journal of Pharmacokinetics and Biopharmaceutics 4: 427–441 (1976).PubMedCrossRefGoogle Scholar
  20. Clarke, J.T.; Libke, R.D.; Regamey, C. and Kirby, W.M.M.: Comparative pharmacokinetics of amikacin and kanamycin. Clinical Pharmacology and Therapeutics 15: 610–616 (1974).PubMedGoogle Scholar
  21. Colburn, W.A.; Schentag, J.J.; Jusko, W.J. and Gibaldi, M.: A model for the prospective identification of the prenephrotoxic state during gentamicin therapy. Journal of Pharmacokinetics and Biopharmaceutics 6: 179–186 (1978).PubMedCrossRefGoogle Scholar
  22. Colding, H.; Vejlsgaard, R.; Hendel, J.; Hvidberg, E.F.; Kampmann, J.P. and Sardemann, H.: Amikacin in newborn infants: summary of pharmacokinetics and recommendation for dosage. Journal of Infectious Diseases 134 (Suppl): S342 (1976).CrossRefGoogle Scholar
  23. Cutler, R.E.; Gyselynck, A.M.; Fleet, W.P. and Forrey, A.W.: Correlation of serum creatinine concentration and gentamicin half-life. Journal of American Medical Association 219: 1037–1041 (1972).CrossRefGoogle Scholar
  24. Cutler, R.E. and Orme, B.M.: Correlation of serum creatinine concentration and kanamycin half-life. Journal of American Medical Association 209: 539–542 (1969).CrossRefGoogle Scholar
  25. Daigneault, R.; Gagne, M. and Brazeau, M.: A comparison of two methods of gentamicin assay: an enzymatic procedure and an agar diffusion technique. Journal of Infectious Diseases 130: 642–645 (1974).PubMedCrossRefGoogle Scholar
  26. Danish, M.; Schultz, R. and Jusko, W.J.: Pharmacokinetics of gentamicin and kanamycin during hemodialysis. Antimicrobial Agents and Chemotherapy 6: 841–847 (1974).PubMedCrossRefGoogle Scholar
  27. Dettli, L.: Individualization of drug dosage in patients with renal disease. Medical Clinics of North America 58: 977–985 (1974a).PubMedGoogle Scholar
  28. Dettli, L.C.: Drug dosage in patients with renal disease. Clinical Pharmacology and Therapeutics 16: 274–280 (1974b).PubMedGoogle Scholar
  29. Dettli, L.; Spring, P. and Ryter, S.: Multiple dose kinetics and drug dosage in patients with kidney disease. Acta Pharmacologica Toxicologica 29 (Suppl): 221–224 (1971).Google Scholar
  30. Driessen, O.M.J.; Sorgedrager, N.; Michel, M.F.; Kerrebijn, K.F. and Hermans, J.: Pharmacokinetic aspects of therapy with ampicillin and kanamycin in newborn infants. European Journal of Clinical Pharmacology 13: 449–457 (1978).CrossRefGoogle Scholar
  31. Dvorchik, B.H. and Vesell, E.S.: Significance of error associated with use of the one-compartment formula to calculate clearance of thirty-eight drugs. Clinical Pharmacology and Therapeutics 23: 617–623 (1978).PubMedGoogle Scholar
  32. Echeverria, P.; Siber, G.R.; Paisley, J.; Smith, A.L.; Smith, D.H. and Jaffe, N.: Age-dependent dose-response to gentamicin. Journal of Pediatrics 87: 805–808 (1975).PubMedCrossRefGoogle Scholar
  33. Editorial: Intrathecal antibiotics in purulent meningitis. Lancet 2: 1068 (1976).Google Scholar
  34. Edwards, C.Q.; Smith, C.R.; Baugham, K.L.; Rogers, J.F. and Leitman, P.S.: Concentrations of gentamicin and amikacin in human kidneys. Antimicrobial Agents and Chemotherapy 9: 925–927 (1976).PubMedCrossRefGoogle Scholar
  35. Erlanson, R. and Lundgren, A.: Ototoxic side effects following treatment with streptomycin, dihydrostreptomycin and kanamycin. Connection with dosage and renal function; preventive measures. Acta Medica Scandinavica 176: 147–163 (1964).Google Scholar
  36. Ervin, F.R.; Bullock, W.E. and Nuittall, C.E.: Inactivation of gentamicin by penicillins in patients with renal failure. Antimicrobial Agents and Chemotherapy 9: 1004–1011 (1976).PubMedCrossRefGoogle Scholar
  37. Evans, W.E.; Feldman, S.; Barker, L.E.; Ossi, M. and Chaudhary, S.: Use of gentamicin serum levels to individualize therapy in children. Journal of Pediatrics 93: 133–137 (1978).PubMedCrossRefGoogle Scholar
  38. Eykyn, S.; Phillips, I. and Ridley, M.: Gentamicin plus carbenicillin. Lancet 1: 545–546 (1971).PubMedCrossRefGoogle Scholar
  39. Fabre, J. and Balant, L.: Renal failure, drug pharmacokinetics and drug action. Clinical Pharmacokinetics 1: 99–120 (1976).PubMedCrossRefGoogle Scholar
  40. Feld, R.; Valdivieso, M.; Bodey, G.P. and Rodriguez, V.: A comparative trial of sisomicin therapy by intermittent versus continuous infusion. American Journal of The Medical Sciences 274: 179–188 (1977).PubMedCrossRefGoogle Scholar
  41. Follath, F.; Spring, P.; Wenk, M.; Bente, L.Z. and Dettli, L.: Comparative pharmacokinetics of sisomicin and netilmicin in healthy volunteers. Current Chemotherapy. Proceedings of the 10th International Congress of Chemotherapy, Zurich, Switzerland, September 18–23, 1977, p.979 (American Society for Microbiology, Washington 1978).Google Scholar
  42. Garrett, E.R.: Pharmacokinetics and clearances related to renal processes. International Journal of Clinical Pharmacology and Biopharmacy 16: 155–172 (1978).PubMedGoogle Scholar
  43. Gibson, T.P. and Nelson, H.A.: Drug kinetics and artificial kidneys. Clinical Pharmacokinetics 2: 403–426 (1977).PubMedCrossRefGoogle Scholar
  44. Gingell, J.C. and Waterworth, P.M.: Dose of gentamicin in patients with normal renal function and renal impairment. British Medical Journal 2: 19–22 (1968).PubMedCrossRefGoogle Scholar
  45. Goitein, K.; Michel, J. and Sacks, T.: Penetration of parenterally administered gentamicin into the cerebrospinal fluid in experimental meningitis. Chemotherapy (Basel) 21: 181–188 (1975).Google Scholar
  46. Gordon, R.C.; Regamey, C. and Kirby, W.M.M.: Serum binding of the aminoglycoside antibiotics. Antimicrobial Agents and Chemotherapy 2: 214–216 (1972).PubMedCrossRefGoogle Scholar
  47. Guignard, J.P.; Torrado, A.; Mazouni, S.M. and Gautier, E.: Renal function in respiratory distress syndrome. Journal of Pediatrics 88: 845–850 (1976).PubMedCrossRefGoogle Scholar
  48. Gwilt, R.P. and Perrier, D.: Plasma protein binding and distribution characteristics of drugs as indices of their hemodialyzability. Clinical Pharmacology and Therapeutics 24: 154–161 (1978).PubMedGoogle Scholar
  49. Gyselynck, A.M.; Forrey, A. and Cutler, R.E.: Pharmacokinetics of gentamicin: distribution and plasma renal clearance. Journal of Infectious Diseases 124 (Suppl): S70–S76 (1971).PubMedCrossRefGoogle Scholar
  50. Halpren, B.A.; Axline, S.F.; Coplon, N.S. and Brown, D.M.: Clearance of gentamicin during hemodialysis: comparison of four artificial kidneys. Journal of Infectious Diseases 133: 627–636 (1976).PubMedCrossRefGoogle Scholar
  51. Hoecker, J.L.; Pickering, L.K.; Swaney, J.; Kramer, W.G.; Van Eys, J.; Feldman, S. and Kohl, S.: Clinical pharmacology of tobramycin in children. Journal of Infectious Diseases 137: 592–596 (1978).PubMedCrossRefGoogle Scholar
  52. Hoffler, D.; Koeppe, P. and Demers, H.G.: Pharmacokinetics of amikacin for treatment of urinary tract infections in patients with reduced renal function. Journal of Infectious Diseases 134 (Suppl): S369–S373 (1976).PubMedCrossRefGoogle Scholar
  53. Holt, H.A.; Broughall, J.M.; McCarthy, M. and Reeves, D.S.: Interactions between aminoglycoside antibiotics and carbenicillin or ticarcillin. Infection 4: 107–109 (1976).PubMedCrossRefGoogle Scholar
  54. Howard, J.B. and McCracken, G.H.: Reappraisal of kanamycin usage in neonates. Journal of Pediatrics 86: 949–956 (1975).PubMedCrossRefGoogle Scholar
  55. Howard, J.B.; McCracken, G.H.; Trujillo, H. and Mohs, E.: Amikacin in newborn infants: comparative pharmacology with kanamycin and clinical efficacy in 45 neonates with bacterial diseases. Antimicrobial Agent and Chemotherapy 10: 205–210 (1976).CrossRefGoogle Scholar
  56. Hull, J.H. and Sarubbi, F.A.: Gentamicin serum concentrations: pharmacokinetic predictions. Annals of Internal Medicine 85: 183–189 (1976).PubMedGoogle Scholar
  57. Humbert, G.; Fillastre, J.P.; Leroy, A. and Oksenhendler, G.: Pharmacokinetics of sisomicin in the normal and in impaired renal function. Infection 4: 393–402 (1976).CrossRefGoogle Scholar
  58. Humbert, G.; Leroy, A.; Fillastre, J.P. and Oksenhendler, G.: Pharmacokinetics of netilmicin in the presence of normal or impaired renal function. Antimicrobial Agents and Chemotherapy 14: 40–44 (1978).PubMedCrossRefGoogle Scholar
  59. Ishiyama, S.; Sakabe, T.; Ushio, S.; Furuhashi, M.; Takahashi, U.; Kasagi, T.; Nagasaki, S.; Kawakami, I.; Nishioka, N.; Iyakayama, I.; Oshima, S.; Iwai, S. and Iwamoto, H.: A clinical and clinicolaboratory study of gentamicin. Chemotherapy (Tokyo) 15: 361–369 (1967).Google Scholar
  60. Israel, K.S.; Welles, J.S. and Black, H.R.: Aspects of the pharmacology and toxicology of tobramycin in animals and humans. Journal of Infectious Diseases 134 (Suppl): S97–S103 (1976).PubMedCrossRefGoogle Scholar
  61. Jaffe, G.; Meyers, B.R. and Hirschman, S.Z.: Pharmacokinetics of tobramycin in patients with stable renal impairment, patients undergoing peritoneal dialysis, and patients on chronic hemodialysis. Antimicrobial Agents and Chemotherapy 5: 611–616 (1974).PubMedCrossRefGoogle Scholar
  62. Jahre, J.A.; Kwung, P.F. and New, H.C.: Kinetics of netilmicin and gentamicin. Clinical Pharmacology and Therapeutics 23: 591–597 (1978).PubMedGoogle Scholar
  63. Jerauld, R. and Silverblatt, F.J.: Effect of N’-methylnicotinamide on the renal accumulation of gentamicin in rats. Antimicrobial Agents and Chemotherapy 13: 893–894 (1978).PubMedCrossRefGoogle Scholar
  64. Jusko, W.J.; Lewis, G.P. and Schmitt, G.W.: Ampicillin and metacillin pharmacokinetics in normal anephric subjects. Clinical Pharmacology and Therapeutics 14: 90–99 (1973).PubMedGoogle Scholar
  65. Kahlmeter, G.; Jonsson, S. and Kamme, C.: Multiple-compartment pharmacokinetics of tobramycin. Current Chemotherapy. Proceedings of the 10th International Congress of Chemotherapy, Zurich, Switzerland, September 18–23, 1977, p. 912 (American Society for Microbiology, Washington 1978).Google Scholar
  66. Kahlmeter, C. and Kamme, G: Prolonged excretion of gentamicin in a patient with unimpaired renal function. Lancet 1: 286 (1975).PubMedCrossRefGoogle Scholar
  67. Kaiser, A.B. and McGee, Z.A.: Aminoglycoside therapy of gram-negative bacillary meningitis. New England Journal of Medicine 293: 1215–1220 (1975).PubMedCrossRefGoogle Scholar
  68. Kaplan, J.M.; McCracken, G.H.; Thomas, M.L. Horton, L.J. and Davis, H.: Clinical pharmacology of tobramycin in newborns. American Journal of Diseases of Childhood 125: 656–660 (1973).Google Scholar
  69. Kaye, D.; Levison, E. and Labovitz, E.D.: The unpredictability of serum concentrations of gentamicin: pharmacokinetics of gentamicin in patients with normal and abnormal renal function. Journal of Infectious Diseases 130: 150–154 (1974).PubMedCrossRefGoogle Scholar
  70. Klastersky, J.; Geuning, G; Mouawad, E. and Daneau, D.: Endotracheal gentamicin in bronchial infections in patients with tracheostomy. Chest 61: 117–120 (1972).PubMedCrossRefGoogle Scholar
  71. Klein, J.O.; Herschel, M.; Therakan, R.M. and Ingall, D.: Gentamicin in serious neonatal infections: absorption, excretion, and clinical results in 25 cases. Journal of Infectious Diseases 124 (Suppl): S224–S231 (1971).PubMedCrossRefGoogle Scholar
  72. Konomi, K.; Yamamoto, H.; Egashira, K.; Kawauchi, Y.; Furusawa, T. and Hisatsugu, T.: Basic and clinical studies of tobramycin in the field of biliary tract infections and other surgical infections. Chemotherapy (Tokyo) 23: 1239–1245 (1975).Google Scholar
  73. Kunin, C.M. and Finland, M.: Persistence of antibiotics in blood of patients with acute renal failure. III. Penicillin, streptomycin, erythromycin and kanamycin. Journal of Clinical Investigation 38: 1509–1519 (1959).Google Scholar
  74. Leroy, A.; Humbert, G.; Oksenhendler, G. and Fillastre, J.P.: Comparative pharmacokinetics of lividomycin, amikacin and sisomicin in normal subjects and in uraemic patients. Journal of Antimicrobial Chemotherapy 2: 373–381 (1976).PubMedCrossRefGoogle Scholar
  75. Leroy, A.; Humbert, G.; Oksenhendler, G. and Fillastre, J.P.: Pharmacokinetics of aminoglycosides in subjects with normal and impaired renal function. Antibiotics Chemotherapy 25: 163–180 (1978).Google Scholar
  76. Letourneau-Saheb, L.; Lapierre, L.; Daigneault, R.; Prud’Homme, M.; St-Louis, G. and Sirois, G.: Gentamicin pharmacokinetics during hemodialysis in patients suffering from chronic renal failure. International Journal of Clinical Pharmacology and Biopharmacy 15: 116–120 (1977).PubMedGoogle Scholar
  77. Levison, M.E. and Kaye, D.: Carbenicillin plus gentamicin. Lancet 2: 45–46 (1971).PubMedCrossRefGoogle Scholar
  78. Levy, J. and Klastersky, J.: Correlation of serum creatinine concentration and amikacin half-life. Journal of Clinical Pharmacology 15: 705–707 (1975).PubMedGoogle Scholar
  79. Lockwood, W.R. and Bower, J.D.: Tobramycin and gentamicin concentrations in the serum of normal and anephric patients. Antimicrobial Agents and Chemotherapy 3: 125–129 (1973).PubMedCrossRefGoogle Scholar
  80. Lode, H.; Grunert, K.; Koeppe, P. and Langmaack, H.: Pharmacokinetic and clinical studies with amikacin, a new aminoglycoside antibiotic. Journal of Infectious Diseases 134 (Suppl): S316–S332 (1976).PubMedCrossRefGoogle Scholar
  81. Loirat, P.; Rohan, J.; Baillet, A.; Beaufils, F.; David, R. and Chapman, P.: Increased glomerular filtration rate in patients with major burns and its effect on the pharmacokinetics of tobramycin. New England Journal of Medicine 299: 915–919 (1978).PubMedCrossRefGoogle Scholar
  82. Luft, F.C.; Brannon, D.R.; Stopes, L.L.; Costello, R.J.; Sloan, R.S. and Maxwell, D.R.: Pharmacokinetics of netilmicin in patients with renal impairment and in patients on dialysis. Antimicrobial Agents and Chemotherapy 14: 403–407 (1978).PubMedCrossRefGoogle Scholar
  83. Luft, F.C.; Patel, V.; Moo, N.Y.; Patel, B. and Kleit, S.A.: Experimental aminoglycoside nephrotoxicity. Journal of Laboratory and Clinical Medicine 86: 213–220 (1975).PubMedGoogle Scholar
  84. Lumholtz, B.; Kampmann, J.; Siersback-Nielsen, K. and Molholm-Hansen, J.: Dosage regimen of kanamycin and gentamicin. Acta Medica Scandinavica 196: 521–524 (1974).PubMedCrossRefGoogle Scholar
  85. Luthy, R.: Aminoglycokosid-antibiotika aus klinischer sicht. Schweizerische Medizinische Wochenschrift 106: 450–455 (1976).PubMedGoogle Scholar
  86. Lynn, B.: Carbenicillin plus gentamicin. Lancet 1: 659 (1971).Google Scholar
  87. Madhavan, T.; Yaremchuk, K.; Levin, N.; Pohdol, D.; Burch, K.; Fisher, E.; Cox, F. and Quinn, E.L.: Effect of renal failure and dialysis on the serum concentrations of the aminoglycoside amikacin. Antimicrobial Agents and Chemotherapy 10: 464–466 (1976).PubMedCrossRefGoogle Scholar
  88. Malacoff, R.F.; Finkelstein, F.O. and Andriole, V.T.: Effect of peritoneal dialysis on serum levels of tobramycin and clindamycin. Antimicrobial Agents and Chemotherapy 8: 574–580 (1975).PubMedCrossRefGoogle Scholar
  89. Mariel, C. and Pechere, J.G: Diffusion dans le liquid cephalorachidien de la gentamicine injectee par voir intramusculaire. Etude chez 5 enfants atteints de meningites purulentes. Therapie 25: 511–514 (1971).Google Scholar
  90. Mariel, C.; Veyssier, P. and Pechere, J.G: Dosage de gentamicin dans le liquide cephalorachidien apres injections lombaires; resultats observes chez 22 malades adultes et enfants. Semaine des Hopitaux de Paris 48: 3543–3547 (1972a).PubMedGoogle Scholar
  91. Mariel, C.; Veyssier, P.; Pechere, J.C. and DeCerner, E.: Urinary pH and excretion of gentamicin. British Medical Journal 2: 405 (1972b).CrossRefGoogle Scholar
  92. Marks, M.L.; Prentice, R.; Swarson, R.; Cotton, E.K. and Eickhoff, T.C.: Carbenicillin and gentamicin: pharmacologic studies in patients with cystic fibrosis and Pseudomonas pulmonary infections. Journal of Pediatrics 79: 822–828 (1971).PubMedCrossRefGoogle Scholar
  93. Marks, M.I.; Vose, A.; Hammerberg, S. and Dugal, R.: Clinico-pharmacological studies of sisomicin in ill children. Antimicrobial Agents and Chemotherapy 13: 753–758 (1978).PubMedCrossRefGoogle Scholar
  94. Mawer, G.E.; Ahmad, R.; Dobbs, S.M.; McGough, J.G.; Lucas, S.B. and Tooth, J.A.: Prescribing acids for gentamicin. British Journal of Clinical Pharmacology 1: 45–50 (1974).PubMedCrossRefGoogle Scholar
  95. Mawer, G.E. and Lucas, S.B.: Nomogram for kanamycin dosage. Lancet 2: 45 (1972).PubMedCrossRefGoogle Scholar
  96. Mayhew, J.W. and Gorback, S.L.: Gas-liquid chromatographic method for the assay of aminoglycoside antibiotics in serum. Journal of Chromatography 151: 133–146 (1978).PubMedCrossRefGoogle Scholar
  97. McCloskey, R.V. and Becker, C.G.: Evaluation of the Cutler-Orme method for administration of kanamycin during renal failure. Antimicrob. Agents Chemother. 2: 161–164 (1971).Google Scholar
  98. McCracken, G.H.; Chrane, D.F. and Thomas, M.L.: Pharmacologic evaluation of gentamicin in newborn infants. Journal of Infectious Diseases 124 (Suppl): S214–S223 (1971a).PubMedCrossRefGoogle Scholar
  99. McCracken, G.H.; West, N.R. and Horton, L.J.: Urinary excretion of gentamicin in the neonatal period. Journal of Infectious Diseases 123: 257–262 (1971b).PubMedCrossRefGoogle Scholar
  100. McCrae, W.M.; Raeburn, J.A. and Hanson, E.J.: Tobramycin therapy of infections due to Pseudomonas aeruginosa in patients with cystic fibrosis: effect of dosage and concentration of antibiotic in sputum. Journal of Infectious Diseases 134 (Suppl): S191–S193 (1976).PubMedCrossRefGoogle Scholar
  101. McHenry, M.C.; Gavan, T.L.; Gifford, R.W.; Geurkink, N.A.; van Ommen, R.A.; Town, M.A. and Wagner, J.G.: Gentamicin dosages for renal insufficiency: adjustments based on endogenous creatinine clearance and serum creatinine concentration. Annals of Internal Medicine 74: 192–197 (1971).PubMedGoogle Scholar
  102. McHenry, M.C.; Wagner, J.G.; Hall, P.M.; Vidt, D.G. and Gavan, T.L.: Pharmacokinetics of amikacin in patients with impaired renal function. Journal of Infectious Diseases 134 (Suppl): S343–S354 (1976).PubMedCrossRefGoogle Scholar
  103. McLaughlin, J.E. and Reeves, D.S.: Clinical and laboratory evidence for inactivation of gentamicin by carbenicillin. Lancet 1: 261–264 (1971).PubMedCrossRefGoogle Scholar
  104. Meunier-Carpentier, F.; Staquet, M. and Klastersky, J.: Comparative study of three routes of administration of sisomicin. Journal of Clinical Pharmacology 16: 625–630 (1976).PubMedGoogle Scholar
  105. Meyers, B.R. and Hirschman, S.Z.: Pharmacologic studies on tobramycin and comparison with gentamicin. The Journal of Clinical Pharmacology 12: 321–324 (1972).Google Scholar
  106. Meyers, B.R.; Hirschman, S.Z.; Yancovitz, S. and Ribner, B.: Pharmacokinetic parameters of sisomicin. Antimicrobial Agents and Chemotherapy 10: 25–27 (1976).PubMedCrossRefGoogle Scholar
  107. Michelson, P.A.; Miller, W.A.; Warner, J.F.; Ayers, L.W. and Boxenbaum, H.G.: Multiple dose pharmacokinetics of gentamicin in man: evaluation of the Jellife nomogram and the adjustment of dosage in patients with renal impairment; in Benet (Ed) The Effect of Disease States on Drug Pharmacokinetics, p. 155 (Academy of Pharmaceutical Sciences, Washington 1976).Google Scholar
  108. Moellering, R.C. and Fisher, E.G.: Relationship of intraventricular gentamicin levels to cure of meningitis. Journal of Pediatrics 81: 534–537 (1972).PubMedCrossRefGoogle Scholar
  109. Myers, D.R.; DeFehr, J.; Bennett, W.M.; Porter, G.A. and Olsen, G.D.: Gentamicin binding to serum and plasma proteins. Clinical Pharmacology and Therapeutics 23: 356–360 (1978a).PubMedGoogle Scholar
  110. Myers, M.G.; Roberts, R.J. and Mirhij, N.J.: Effects of gestational age, birth weight and hypoxemia on pharmacokinetics of amikacin in serum of infants. Antimicrobial Agents and Chemotherapy 11: 1027–1032 (1977).PubMedCrossRefGoogle Scholar
  111. Myers, M.G.; Roberts, R.J. and Mirhij, N.J.; Effects of hypoxemia upon aminoglycoside serum pharmacokinetics. Current Chemotherapy. Proceedings of the 10th International Congress of Chemotherapy, Zurich, Switzerland, September 18–23, 1977, p.994 (American Society for Microbiology, Washington 1978b).Google Scholar
  112. Naber, K.G.; Westenfelder, S.R. and Madsen, P.O.: Pharmacokinetics of the aminoglycoside antibiotic tobramycin in humans. Antimicrobial Agents and Chemotherapy 3: 469–473 (1973).PubMedCrossRefGoogle Scholar
  113. Nation, R.L.; Peng, G.W.; Chiou, W.L. and Malow, J.: Comparison of gentamicin C1 and (C1a, C2) levels in patients. European Journal of Clinical Pharmacology 13: 459–462 (1978).CrossRefGoogle Scholar
  114. Neu, H.C.; Aminoglycosides: do we need new agents?. Drugs 12: 161–165 (1976).PubMedCrossRefGoogle Scholar
  115. Neu, H.C.; Appel, G.B.; Parry, M.F.; Garvey, G.J. and Jacob, G.: Pharmacokinetics of sisomicin in normal patients and those with depressed renal function. Infection 4: 403–405 (1976).CrossRefGoogle Scholar
  116. Noone, P.; Beale, D.F.; Pollock, S.S.; Perera, M.R.; Amirak, I.D.; Fernando, O.N. and Moorhead, J.F.: Monitoring aminoglycoside use in patients with severely impaired renal function. British Medical Journal 2: 470–473 (1978).PubMedCrossRefGoogle Scholar
  117. Noone, P.; Parsons, T.M.C.; Pattison, J.R.; Slack, R.C.B.; Garfield-Davies, D. and Hughes, K.: Experience in monitoring gentamicin therapy during treatment of serious gram-negative sepsis. British Medical Journal 1: 477–481 (1974).PubMedCrossRefGoogle Scholar
  118. Noone, P. and Pattison, J.R.: Therapeutic implications of interaction of gentamicin and penicillins. Lancet 2: 575–578 (1971).PubMedGoogle Scholar
  119. Odio, W.; Van Laer, E. and Klastersky, J.: Concentrations of gentamicin in bronchial secretions after intramuscular and endotracheal administration. Journal of Clinical Pharmacology 15: 518–524 (1975).PubMedGoogle Scholar
  120. Orme, B.M. and Cutler, R.E.: The relationship between kanamycin pharmacokinetics its distribution and renal function. Clinical Pharmacology and Therapeutics 10: 543–550 (1969).PubMedGoogle Scholar
  121. Pechere, J.C. and Dugal, R.: Pharmacokinetics of intravenously administered tobramycin in normal volunteers and in renal-impaired and hemodialyzed patients. Journal of Infectious Diseases 134 (Suppl): S118–S124 (1976).PubMedCrossRefGoogle Scholar
  122. Pechere, J.C.; Roy, B. and Dugal, R.: Distribution and elimination kinetics of intravenously and intramuscularly administered tobramycin in man. International Journal of Clinical Pharmacology and Biopharmacy 14: 313–318 (1976a).PubMedGoogle Scholar
  123. Pechere, J.C.; Pechere, M.M. and Dugal, R.: Clinical pharmacokinetics of sisomicin: dosage schedules in renal-impairment patients. Antimicrobial Agents and Chemotherapy 9: 761–765 (1976b).PubMedCrossRefGoogle Scholar
  124. Pechere, J.C.; Pechere, M.M. and Dugal, R.: Clinical pharmacokinetics of sisomicin: two-compartment model analysis of serum data after I.V. and I.M. administration. European Journal of Clinical Pharmacology 10: 251–256 (1976c).CrossRefGoogle Scholar
  125. Pechere, J.C.; Dugal, R. and Pechere, M.M.: Kinetics of netilmicin in man. Clinical Pharmacology and Therapeutics 23: 677–684 (1978a).PubMedGoogle Scholar
  126. Pechere, J.C.; Dugal, R. and Pechere, M.M.: Pharmacokinetics of netilmicin in renal insufficiency and haemodialysis. Clinical Pharmacokinetics 3: 395–406 (1978b).PubMedCrossRefGoogle Scholar
  127. Pechere, J.C.; Dugal, R. and Pechere, M.M.: Pharmacokinetics of intravenous amikacin after rapid and slow infusion with special reference to hemodialysis. European Journal of Drug Metabolism and Pharmacokinetics (In press, 1979).Google Scholar
  128. Pennington, J.E. and Reynolds, H.Y.: Concentrations of gentamicin and carbenicillin in bronchial secretions. Journal of Infectious Diseases 128: 63–68 (1973a).PubMedCrossRefGoogle Scholar
  129. Pennington, J.E. and Reynolds, H.Y.: Tobramycin in bronchial secretions. Antimicrobial Agents and Chemotherapy 4: 299–301 (1973b).PubMedCrossRefGoogle Scholar
  130. Pennington, J.E.: Dale, D.C.: Reynolds, H.Y. and MacLowry, J.D.: Gentamicin sulfate pharmacokinetics: lower levels of gentamicin in blood during fever. Journal of Infectious Diseases 132: 270–275 (1975).Google Scholar
  131. Pennington, J.E. and Reynolds, H.Y.: Pharmacokinetics of gentamicin sulfate in bronchial secretions. Journal of Infectious Diseases 131: 158–162 (1975).PubMedCrossRefGoogle Scholar
  132. Perrier, D. and Gibaldi, M.: Estimation of drug elimination in renal failure. Journal of Clinical Pharmacology 13: 458–462 (1973).PubMedGoogle Scholar
  133. Peterson, L.R.; Hall, W.H.; Zinneman, H.H. and Gerding, D.N.: Standardization of a preparative ultracentrifuge method for quantitative determination of protein binding of seven antibiotics. Journal of Infectious Diseases 136: 778–783 (1977).PubMedCrossRefGoogle Scholar
  134. Pijck, J.; Hallynck, T.; Soep, H.; Baert, L.; Daneeis, R. and Boelaert, J.: Pharmacokinetics of amikacin in patients with renal insufficiency; relation of half-life and creatinine clearance. Journal of Infectious Diseases 134 (Suppl): S331–S341 (1976).PubMedCrossRefGoogle Scholar
  135. Pines, A.; Raafat, H. and Plucinski, K.: Gentamicin and Colistin in chronic purulent bronchial infections. British Medical Journal 2: 543–545 (1967).PubMedCrossRefGoogle Scholar
  136. Pitt, H.A.; Roberts, R.B. and Johnson, W.D.: Gentamicin levels in the human biliary tract. Journal of Infectious Diseases 127: 299–302 (1973).PubMedCrossRefGoogle Scholar
  137. Plantier, J.; Forrey, A.W.; O’Neil, M.A.; Blair, A.D.; Christopher, T.G. and Cutler, R.E.: Pharmacokinetics of amikacin in patients with normal or impaired renal function: radioenzymatic acetylation assay. Journal of Infectious Diseases 134 (Suppl): S323–S329 (1976).PubMedCrossRefGoogle Scholar
  138. Preston, F.W.; Silverman, M.; Henegar, G.C. and Neveril, E.: The excretion of kanamycin in bile and pancreatic fluid. Antibiotics Annals 7: 857–861 (1960).Google Scholar
  139. Rahal, J.J.: Treatment of gram-negative bacillary meningitis in adults. Annals of Internal Medicine 77: 295–302 (1972).PubMedGoogle Scholar
  140. Rahal, J.J.; Hyams, P.J.; Simberkoff, M.S. and Rubinstein, E.: Combined intrathecal and intramuscular gentamicin for gram-negative meningitis: pharmacologic study of 21 patients. New England Journal of Medicine 290: 1394–1398 (1974).PubMedCrossRefGoogle Scholar
  141. Ramirez-Rhonda, C.H.; Holmes, R.K. and Sanford, J.P.: Effects of divalent cations on binding of aminoglycoside antibiotics to human serum proteins and to bacteria. Antimicrobial Agents and Chemotherapy 7: 239–245 (1975).CrossRefGoogle Scholar
  142. Reeves, D.S.: Accuracy of gentamicin assays. Postgraduate Medical Journal 50(Suppl 7): 20–21 (1974a).PubMedGoogle Scholar
  143. Reeves, D.S.: Quality control of gentamicin assays. Lancet 2: 667–688 (1974b).PubMedGoogle Scholar
  144. Regamey, C.; Gordon, R.C. and Kirby, W.M.M.: Comparative pharmacokinetics of tobramycin and gentamicin. Clinical Pharmacology and Therapeutics 14: 396–403 (1973).PubMedGoogle Scholar
  145. Regeur, L.; Colding, H.; Jensen, H. and Kampmann, J.P.: Pharmacokinetics of amikacin during hemodialysis and peritoneal dialysis. Antimicrobial Agents and Chemotherapy 11: 214–218 (1977).PubMedCrossRefGoogle Scholar
  146. Regula, H.; Wieser, O.; Naumann, P.; Wundt, W. and Kleinhuber, U.: Pharmakokinetische Untersuchungen uber sputum-, serum-, und urinkonzentration von gentamicin nach aerosolinhalation. International Journal of Clinical Pharmacology 7: 95–100 (1973).Google Scholar
  147. Riff, L.J. and Jackson, G.G.: Pharmacology of gentamicin in man. Journal of Infectious Diseases 124 (Suppl): S98–S105 (1971a).PubMedCrossRefGoogle Scholar
  148. Riff, L.J. and Jackson, G.G.: Gentamicin plus carbenicillin. Lancet 1: 592 (1971b).PubMedCrossRefGoogle Scholar
  149. Riff, L.J. and Jackson, G.G.: Laboratory and clinical conditions for gentamicin inactivation by carbenicillin. Archives of Internal Medicine 130: 887–891 (1972).PubMedCrossRefGoogle Scholar
  150. Riff, L.J. and Moreschi, G.: Netilmicin and gentamicin: comparative pharmacology in humans. Antimicrobial Agents and Chemotherapy 11: 609–614 (1977).PubMedCrossRefGoogle Scholar
  151. Rodriguez, V.; Bodey, G.P.; Valdivieso, M. and Feld, R.: Clinical pharmacology of sisomicin. Antimicrobial Agents and Chemotherapy 7: 38–41 (1975).PubMedCrossRefGoogle Scholar
  152. Rosdahl, N. and Andersen, J.B.: Aspects of the pharmacology of gentamicin during the neonatal period. Acta Pathologica Microbiologica Scandinavica 81 (Suppl.): 119–123 (1973).Google Scholar
  153. Roth, S.; Naber, K.; Scheer, M.; Gruenwaldt, G. and Lange, H.: Pharmakokinetik von sisomicin bei patienten mit normaler und eingeschrankter nierenfunktion und seine Wirkung bei harnwegsinfektionen. Infection 4: 408–416 (1976).Google Scholar
  154. Rubinstein, E.; Beer-Gehler, G.; Dubner, J.; Hallynek, T. and Wolfstein, I.: Amikacin in the human biliary tract. Current Chemotherapy. Proceedings of the 10th International Congress of Chemotherapy, Zurich, Switzerland, September 18–23, 1977 p.998 (American Society for Microbiology, Washington 1978).Google Scholar
  155. Rubio, T.; Writh, F. and Wellman, L.: Pharmacokinetics of netilmicin in newborn infants. Current Chemotherapy. Proceedings of the 10th International Congress of Chemotherapy, Zurich, Switzerland, September 18–23, 1977 p.977 (American Society for Microbiology, Washington 1978).Google Scholar
  156. Saad, A.F. and Farrar, W.E.: Intracisternal and intrathecal infections of gentamicin in Enterobacter meningitis. Archives of Internal Medicine 134: 738–740 (1974).PubMedCrossRefGoogle Scholar
  157. Sardemann, H.; Colding, H.; Hendel, J.; Kampmann, J.P.; Hvidberg, E.F. and Vejlsgaard, R.: Kinetics and dose calculations of amikacin in the newborn. Clinical Pharmacology and Therapeutics 20: 59–66 (1976).PubMedGoogle Scholar
  158. Sawchuk, R.J. and Zaske, D.E.: Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patients. Journal of Pharmacokinetics and Biopharmaceutics 4: 183–195 (1975).Google Scholar
  159. Sawchuk, R.J.; Zaske, D.E.; Cipolle, R.J.; Wargin, W.A. and Strate, R.G.: Kinetic model for gentamicin dosing with the use of individual patient parameters. Clinical Pharmacology and Therapeutics 21: 362–369 (1977).PubMedGoogle Scholar
  160. Scheid, W.M.; Brown, R.S. and Sande, M.A.: Comparison of netilmicin with gentamicin in the therapy of experimental Escherichia coli meningitis. Antimicrobial Agents and Chemotherapy 13: 899–904 (1978).CrossRefGoogle Scholar
  161. Schentag, J.J. and Jusko, W.J.: Renal clearance and tissue accumulation of gentamicin. Clinical Pharmacology and Therapeutics 22: 364–370 (1977).PubMedGoogle Scholar
  162. Schentag, J.J.; Jusko, W.J.; Vance, J.W.; Cumbo, T.J.; Abrutyn, E.; DeLattre, M. and Gerbracht, L.M.: Gentamicin disposition and tissue accumulation on multiple dosing. Journal of Pharmacokinetics and Biopharmaceutics 5: 559–577 (1977).PubMedCrossRefGoogle Scholar
  163. Schentag, J.J.; Lasezkay, G.; Cumbo, T.J.: Plaut, M.E. and Jusko, W.J.: Accumulation pharmacokinetics of tobramycin. Antimicrobial Agents and Chemotherapy 13: 649–656 (1978a).PubMedCrossRefGoogle Scholar
  164. Schentag, J.J.; Lasezkay, G.; Plaut, M.E.; Jusko, W.J. and Cumbo, T.J.: Comparative tissue accumulation of gentamicin and tobramycin in patients. Journal of Antimicrobial Chemotherapy 4(Suppl A): 23–30 (1978b).PubMedCrossRefGoogle Scholar
  165. Schoenfield. L.J.: Biliary excretion of antibiotics. New England Journal of Medicine 284: 1213–1214 (1971).PubMedCrossRefGoogle Scholar
  166. Schumacher, G.E.: Pharmacokinetic analysis of gentamicin dosage regimens recommended for renal impairment Journal of Clinical Pharmacology 15: 656–665 (1975a).PubMedGoogle Scholar
  167. Schumacher, G.E.: Practical pharmacokinetic techniques for drug consultation and evaluation. IV: Gentamicin blood level versus time profiles of various dosage regimens recommended for renal impairment. Amer. J. Hosp. Pharm. 32: 299–308 (1975b).Google Scholar
  168. Schwartz, S.N.; Pazin, G.J.; Lyon, J.A.; Ho, M. and Pasculle, A.W.: A controlled investigation of the pharmacokinetics of gentamicin and tobramycin in obese subjects. Journal of Infectious Diseases 138: 499–505 (1978).PubMedCrossRefGoogle Scholar
  169. Shah, P.P. and Robson, H.G.: Cerebrospinal fluid penetration of netilmicin, Current Chemotherapy. Proceedings of the 10th International Congress of Chemotherapy, Zurich, Switzerland, September 18–23, 1977 p.981 (American Society for Microbiology, Washington 1978).Google Scholar
  170. Shaw, E.J.; Watson, R.A.A. and Smith, D.S.: Fluoroimmunoassay of serum gentamicin. European Journal of Drug Metabolism and Pharmacokinetics 4: 191–193 (1977).CrossRefGoogle Scholar
  171. Siber, G.R.; Echeverria, P.; Smith, A.L.; Paisley, J.W. and Smith, D.H.: Pharmacokinetics of gentamicin in children and adults. Journal of Infectious Diseases 132: 637–651 (1975).PubMedCrossRefGoogle Scholar
  172. Simon, V.K.; Mosinger, E.U. and Malerczy, V.: Pharmacokinetic studies of tobramycin and gentamicin. Antimicrobial Agents and Chemotherapy 3: 445–450 (1973).PubMedCrossRefGoogle Scholar
  173. Smithivas, T.; Hyams, P.J. and Rahal, J.J.: Gentamicin and ampicillin in human bile. Journal of Infectious Diseases 124 (Suppl): S106–S108 (1971).PubMedCrossRefGoogle Scholar
  174. Spring, P.: Calculation of drug dosage regimens in patients with renal disease: a new nomographic method. International Journal of Clinical Pharmacology 11: 76–80 (1975).Google Scholar
  175. Strausbaugh, L.J.; Mandaleris, C.D. and Sande, M.A.: Comparison of four aminoglycoside antibiotics in the therapy of experimental E. coli meningitis. Journal of Laboratory and Clinical Medicine 89: 692–701 (1977).PubMedGoogle Scholar
  176. Thuillier, C.; Fillastre, J.P.; Leroy, A. and Godin, M.: Gentamicine: etude pharmacocinetique chez l’homme apres administration intramusculaire d’une forte dose. Therapie 33: 357–362 (1978).PubMedGoogle Scholar
  177. Thys, J.P. and Klastersky, J.: Concentrations of sisomicin in serum and in bronchial secretions after intrathecal administration. Current Chemotherapy. Proceedings of the 10th International Congress of Chemotherapy, Zurich, Switzerland, September 18–23, 1977, p.920 (American Society for Microbiology, Washington 1978).Google Scholar
  178. Tobias, J.S.; Wrigley, P.F.M.; Korde, S. and Shaw, E.J.: Nomogram-assisted dosage of tobramycin. Journal of Antimicrobial Chemotherapy 3: 305–309 (1977).PubMedCrossRefGoogle Scholar
  179. Tozer, T.N.: Nomogram for modification of dosage regimens in patients with chronic renal function impairment. Journal of Pharmacokinetics and Biopharmaceutics 2: 13–28 (1974).CrossRefGoogle Scholar
  180. Trestman, I.; Parsons, J.; Santoro, J.; Goodhart, G. and Kaye, D.: Pharmacology and efficacy of netilmicin. Antimicrobial Agents and Chemotherapy 13: 832–836 (1978).PubMedCrossRefGoogle Scholar
  181. Trnovec, T.; Navarova, J.; Kettner, M.; Greguskova, M.; Bezek, S.; Gajdosik, K. and Kyselov, A.: Pharmacokinetics of gentamicin administered intratracheally to rats. Antimicrobial Agents and Chemotherapy 14: 165–167 (1978).PubMedCrossRefGoogle Scholar
  182. Vacek, V.: Hejzlar, M. and Skalova, M.: Penetration of antibiotics into the cerebrospinal fluid in inflammatory conditions. III gentamicin. International Journal of Clinical Pharmacology 2: 277–279 (1969).Google Scholar
  183. Valdivieso, M.; Feld, R.; Rodriguez, V. and Bodey, G.P.: Amikacin therapy in infections in neutropenic patients. American Journal of the Medical Sciences 270: 453–463 (1975).PubMedCrossRefGoogle Scholar
  184. Wagner, J.G.: A safe method for rapidly achieving plasma concentration plateaus. Clinical Pharmacology and Therapeutics 16: 691–700 (1974).PubMedGoogle Scholar
  185. Waterworth, P.M.: Which gentamicin assay method is the most practicable. Journal of Antimicrobial Chemotherapy 3: 1–8 (1977).PubMedCrossRefGoogle Scholar
  186. Weibert, R.T. and Keane, W.F.: Carbenicillin-gentamicin interaction in acute renal failure. American Journal of Hospital Pharmacy 34: 1137–1139 (1977).PubMedGoogle Scholar
  187. Welling, P.G.; Baumueller, A.; Lau, C.C. and Madsen, P.O.: Netilmicin pharmacokinetics after single intravenous doses to elderly male patients. Antimicrobial Agents and Chemotherapy 12: 328–334 (1977).PubMedCrossRefGoogle Scholar
  188. Welling, P.G. and Craig, W.A.: Pharmacokinetics in disease states modifying renal function; in Benet (Ed) The Effect of Disease States on Drug Pharmacokinetics, p. 155 (Academy of Pharmaceutical Sciences, Washington 1976).Google Scholar
  189. Welling, P.G.; Craig, W.A. and Kunin, C.M.: Prediction of drug dosage in patients with renal failure using data derived from normal subjects. Clinical Pharmacology Therapeutics 18: 45–52 (1975).Google Scholar
  190. Welling, P.G.; Mosegaard, A. and Madsen, O.: Sisomicin treatment of complicated urinary tract infections: efficacy, tolerance and pharmacokinetics. Journal of Clinical Pharmacology 14: 567–573 (1974).PubMedGoogle Scholar
  191. Wennberg, R.P. and Rasmussen, F.: Effect of gentamicin on albumin binding of bilirubin. Pediatric Pharmacology and Therapeutics 86: 611–613 (1975).Google Scholar
  192. Westenfelder, S.R.; Welling, P.G. and Madsen, P.O.: Efficacy and pharmacokinetics of tobramycin in patients with chronic urinary tract infections and various degrees of renal impairment. Infection 2: 66–69 (1974).Google Scholar
  193. Whelton, A.; Carter, G.G.; Craig, T.J.; Bryant, H.H.; Herbst, D.V. and Walker, W.G.: Comparison of the intrarenal disposition of tobramycin and gentamicin: therapeutic and toxicologic answers. Journal of Antimicrobial Chemotherapy 4 (Suppl): 13–22 (1978).PubMedCrossRefGoogle Scholar
  194. Whelton, A. and Walker, W.G.: Intrarenal antibiotic distribution in health and disease. Kidney International 6: 131–137 (1974).PubMedCrossRefGoogle Scholar
  195. Wieser, O.; Regula, H. and Wundt, W.: Die ausscheidung von gentamicin der bronchialbaum. Deutsche Medizinische Wochenschrift 96: 870–872 (1971).PubMedCrossRefGoogle Scholar
  196. Wilkinson, P.J.; Belohradsy, B.H.; Marget, W. and von Hattingberg, H.M.: Pharmacokinetics of amikacin in the newborn and young infant. Current Chemotherapy. Proceedings of the 10th International Congress of Chemotherapy, Zurich, Switzerland, September 18–23, 1977, p.996 (American Society for Microbiology, Washington 1978).Google Scholar
  197. Winters, R.E.; Litwack, K.D. and Hewitt, W.L.: Relation between dose and levels of gentamicin in blood. Journal of Infectious Diseases 124 (Suppl): S90–S97 (1971).PubMedCrossRefGoogle Scholar
  198. Wolf, A.V.; Remp, D.G. and Kiley, J.E.: Artificial kidney function: kinetics of hemodialysis. Journal of Clinical Investigation 30: 1062–1070 (1951).PubMedCrossRefGoogle Scholar
  199. Wong, G.A.; Pierce, T.H.; Goldstein, E. and Hoeprich, P.D.: Penetration of antimicrobial agents into bronchial secretions. American Journal of Medicine 59: 219–223 (1975).PubMedCrossRefGoogle Scholar
  200. Wood, M.J. and Farrell, W.: Comparison of urinary excretion of tobramycin and gentamicin in adults. Journal of Infectious Diseases 134 (Suppl): S133–S136 (1976).PubMedCrossRefGoogle Scholar
  201. Woods, J.T.; Bryan, L.E.; Chan, G. and Schiff, D.: Gentamicin and albumin binding: an in vivo study. Journal of Pediatrics 89: 483–486 (1976).PubMedCrossRefGoogle Scholar
  202. Yates, R.A.; Mitchard, M. and Wise, R.: Disposition studies with amikacin after rapid intravenous and intramuscular administration to human volunteers. Journal of Antimicrobial Chemotherapy 4: 335–341 (1978).PubMedCrossRefGoogle Scholar
  203. Yourrassowsky, E.; De Broe, M.E. and Wieme, R.J.: Effect of heparin on gentamicin concentrations in blood. Clinica Chimica Acta 42: 189–191 (1972).CrossRefGoogle Scholar
  204. Zaslow, J.; Counseller, V.S. and Heilman, F.R.: The excretion and concentration of penicillin and streptomycin in the abnormal human biliary tract: I: gall bladder bile. Surgery, Gynecology and Obstetrics 84: 16–20 (1947a).PubMedGoogle Scholar
  205. Zaslow, J.; Counseller, V.S. and Heilman. F.R.: The excretion and concentration of penicillin and streptomycin in the abnormal human biliary tract: II: Hepatic bile. Surgery, Gynecology and Obstetrics 84: 140–152 (1947b).PubMedGoogle Scholar

Copyright information

© ADIS Press Australasia Pty Ltd. 1979

Authors and Affiliations

  • Jean-Claude Pechere
    • 1
    • 2
  • Robert Dugal
    • 1
    • 2
  1. 1.Department of Microbiology, School of MedicineLaval UniversityQuebec CityCanada
  2. 2.Institut National de la Recherche Scientifique (Sante)MontrealCanada

Personalised recommendations